This study has demonstrated that patients receiving additional pertuzumab had an increased progression-free survival (PFS) [31], confirming that effective suppression of both HER2 and ERα are crucial to improve HER2+/HR+ breast cancer treatment. This evidence concerns the gene ERBB2 and breast carcinoma.